Startup
Working on a virus-like particle vaccine platform initially targeting RSV, human metapneumovirus and parainfluenza virus.
Every investor coverage indicates participated in a round AdaptiVax raised.
| Investor | Rounds | Invested |
|---|---|---|
| Biointelect Venturer | Accelerator | - |
Companies AdaptiVax acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming AdaptiVax. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
An Australian infectious-disease incubator has selected six local biotechs to divide $10.48 million from its inaugural funding round, pairing non-dilutive cash with commercialisation support; the program is backed by an earlier MRFF grant.